A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 30 Sep 2024
At a glance
- Drugs BL-M07D1 (Primary) ; Capecitabine
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 17 Sep 2024 Planned number of patients changed from 120 to 46.
- 17 Sep 2024 Planned End Date changed from 1 Jun 2026 to 1 Oct 2026.
- 17 Sep 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Oct 2026.